<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7508070\results\search\disease\results.xml">
  <result pre="new creations are licensed under the identical terms. The coronavirus" exact="disease" post="2019 (COVID-19), which originated from Wuhan in China, has"/>
  <result pre="existing cases. The disease, caused by a novel coronavirus (Severe" exact="acute" post="respiratory syndrome [SARS]-CoV2), has a high rate of transmission"/>
  <result pre="cases. The disease, caused by a novel coronavirus (Severe acute" exact="respiratory" post="syndrome [SARS]-CoV2), has a high rate of transmission mainly"/>
  <result pre="The disease, caused by a novel coronavirus (Severe acute respiratory" exact="syndrome" post="[SARS]-CoV2), has a high rate of transmission mainly through"/>
  <result pre="of the earlier studies claimed a very low incidence of" exact="conjunctivitis" post="in patients with COVID-19 infection. However, a recent study"/>
  <result pre="China reports that almost 31.6% of patients with COVID-19 had" exact="ocular" post="involvement. It was also interesting to note that 91.7%"/>
  <result pre="interesting to note that 91.7% of the patients with COVID-19-related" exact="conjunctivitis" post="tested positive on a nasopharyngeal swab.[2] All suspected cases"/>
  <result pre="transmit the virus in the community. Currently, the treatment for" exact="symptomatic" post="COVID-19 infection is mainly supportive, and the medical fraternity"/>
  <result pre="virus in the community. Currently, the treatment for symptomatic COVID-19" exact="infection" post="is mainly supportive, and the medical fraternity is still"/>
  <result pre="still struggling to find a suitable treatment. Though controlling the" exact="systemic" post="illness is the highest priority of healthcare at present,"/>
  <result pre="present, effective preventive measures to curb the transmission of this" exact="disease" post="are equally important to reduce the overwhelming number of"/>
  <result pre="contain the transmission of the virus in cases of COVID-19" exact="conjunctivitis" post="and not let these cases go away without treatment"/>
  <result pre="let these cases go away without treatment like any other" exact="viral conjunctivitis." post="Even though all COVID-19 cases do not have ocular"/>
  <result pre="viral conjunctivitis. Even though all COVID-19 cases do not have" exact="ocular" post="manifestations, still the viral shedding may occur through tears"/>
  <result pre="all COVID-19 cases do not have ocular manifestations, still the" exact="viral" post="shedding may occur through tears in symptomatic patients as"/>
  <result pre="manifestations, still the viral shedding may occur through tears in" exact="symptomatic" post="patients as well as asymptomatic carriers. Hence, there is"/>
  <result pre="was found to be effective in the treatment of adenoviral" exact="conjunctivitis" post="in a few studies. It is highly effective against"/>
  <result pre="related conjunctivitis, we need to consider interventions to reduce the" exact="viral" post="load on the ocular surface. Frequent Instillation of antibiotic"/>
  <result pre="to consider interventions to reduce the viral load on the" exact="ocular" post="surface. Frequent Instillation of antibiotic and lubricant eye drops"/>
  <result pre="with at least 0.02% BAK in patients with suspected COVID-19" exact="conjunctivitis" post="will reduce the viral load and hamper further individual"/>
  <result pre="BAK in patients with suspected COVID-19 conjunctivitis will reduce the" exact="viral" post="load and hamper further individual colonization and community spread."/>
  <result pre="duties. Marketing and manufacturer of BAK eye drop specifically for" exact="viral conjunctivitis" post="is an unmet need to be considered by the"/>
  <result pre="Marketing and manufacturer of BAK eye drop specifically for viral" exact="conjunctivitis" post="is an unmet need to be considered by the"/>
  <result pre="come. Betadine eye drop is another commonly used compound for" exact="viral conjunctivitis." post="Few well-designed studies have established the efficacy of Betadine"/>
  <result pre="studies have established the efficacy of Betadine eye drops in" exact="viral" post="conjunctivitis.[5] For a case of conjunctivitis with COVID-19, this"/>
  <result pre="Betadine eye drops in viral conjunctivitis.[5] For a case of" exact="conjunctivitis" post="with COVID-19, this preparation may help to reduce the"/>
  <result pre="conjunctivitis with COVID-19, this preparation may help to reduce the" exact="viral" post="load due to its action against a wide range"/>
  <result pre="the use of saline to enhance the virucidal activity of" exact="epithelial" post="cells by increasing intracellular hypochlorite.[6] Rising levels of sodium"/>
  <result pre="a therapeutic avenue to explore to avoid transmission through the" exact="ocular" post="surface. Similar antiviral action may exist in the epithelium"/>
  <result pre="a dual-mode of action and may be considered for blocking" exact="viral" post="entry and exit through the nose as a preventive"/>
  <result pre="COVID-19 infection, oral chloroquine was found effective in reducing the" exact="systemic" post="viral load. 0.03% chloroquine eye drops have been used"/>
  <result pre="infection, oral chloroquine was found effective in reducing the systemic" exact="viral" post="load. 0.03% chloroquine eye drops have been used for"/>
  <result pre="eye drops have been used for the treatment of dry" exact="eye disease" post="in a few studies.[7] This drug may also have"/>
  <result pre="drops have been used for the treatment of dry eye" exact="disease" post="in a few studies.[7] This drug may also have"/>
  <result pre="and further studies may be required for validation. Although COVID-19-related" exact="conjunctivitis" post="is a self-limiting disease, efforts to reduce transmission in"/>
  <result pre="substitutes with minimal side effects may be advocated to suspected" exact="conjunctivitis" post="cases, considering the mammoth task of controlling the ongoing"/>
  <result pre="novel coronavirus in Wuhan, ChinaLancet (London, England)2020395497506 2WuPDuanFLuoCLiuQQuXLiangLet al.Characteristics of" exact="ocular" post="findings of patients with coronavirus disease 2019 (COVID-19) in"/>
  <result pre="England)2020395497506 2WuPDuanFLuoCLiuQQuXLiangLet al.Characteristics of ocular findings of patients with coronavirus" exact="disease" post="2019 (COVID-19) in Hubei Province, ChinaJAMA Ophthalmol2020doi: 101001/jamaophthalmol 20201291"/>
  <result pre="in Hubei Province, ChinaJAMA Ophthalmol2020doi: 101001/jamaophthalmol 20201291 3JunISYHuiKKOSongboPZPerspectives on coronavirus" exact="disease" post="2019 control measures for ophthalmology clinics based on a"/>
 </snippets>
</snippetsTree>
